PMID: 8970246Nov 1, 1996Paper

Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies

Survey of Ophthalmology
T R Walters

Abstract

Clinical trials were conducted to evaluate brimonidine tartrate, an alpha 2-adrenoceptor agonist, for treating chronically elevated intraocular pressure (IOP) and the prophylactic treatment of acute pressure rises. In normal volunteers, brimonidine administered twice daily for five days at concentrations ranging from 0.08-0.5% lowered IOP 16-22% and was well-tolerated ocularly and systemically. In a 28-day study in 186 patients with glaucoma or ocular hypertension, maximum IOP lowering was 27.2% and 30.1% for brimonidine 0.2% and 0.5%, respectively. The most common adverse events were dry mouth fatigue/drowsiness, and blurring, which occurred significantly more frequently with brimonidine 0.5% than 0.2%. Brimonidine 0.5% was tested in 471 patients undergoing argon laser trabeculoplasty (ALT). One drop administered preoperatively, postoperatively or both pre- and postoperatively significantly reduced the number of postoperative IOP spikes (1-2% of patients compared to 23% receiving only vehicle). Systemic hypotension, dry mouth, lid retraction and conjunctival blanching occurred more frequently in patients who received the drug twice. Brimonidine 0.2% twice daily was compared with three times daily in 101 patients. No significan...Continue Reading

References

May 1, 1988·Clinical Pharmacokinetics·D T LowenthalT R MacGregor
Mar 1, 1983·American Journal of Ophthalmology·R N WeinrebK Zweig
Jul 1, 1983·American Journal of Ophthalmology·S C Sullivan
Jul 1, 1981·Archives of Ophthalmology·E HodappM Gordon
Mar 1, 1982·Ophthalmology·J V ThomasC D Belcher
Dec 1, 1995·Archives of Ophthalmology·C B TorisM E Yablonski
Mar 1, 1995·Ophthalmology·C B TorisM E Yablonski
Dec 1, 1995·The British Journal of Ophthalmology·S V AraujoG L Spaeth
Nov 1, 1996·Survey of Ophthalmology·J Burke, M Schwartz

❮ Previous
Next ❯

Citations

Dec 30, 2006·Veterinary Research Communications·S SuwanwipatN Chaiyabutr
Aug 6, 2000·American Journal of Ophthalmology·W C StewartJ A Stewart
Mar 8, 2000·American Journal of Ophthalmology·A M CarlssonR P LeBlanc
May 20, 1999·American Journal of Ophthalmology·D H ShinK D Nguyen
May 30, 2001·Survey of Ophthalmology·M Vidal-SanzM P Villegas-Pérez
Nov 1, 1996·Survey of Ophthalmology·J T Wilensky
Nov 26, 2002·Veterinary Ophthalmology·Kirk N Gelatt, Edward O MacKay
Mar 22, 2003·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Tom MundorfAmy Batoosingh
Feb 19, 2005·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Faruk OztürkSevim Yaman
Sep 29, 2007·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Chan Yun KimGong Je Seong
Aug 26, 1998·Australian and New Zealand Journal of Ophthalmology·W E Gillies, A M Brooks
Mar 12, 1999·BMJ : British Medical Journal·A R FielderM J Moseley
Mar 25, 2008·Therapeutics and Clinical Risk Management·Louis B Cantor
Apr 29, 2011·Experimental Eye Research·Stella Arthur, Louis B Cantor
Nov 1, 1996·Survey of Ophthalmology·J Burke, M Schwartz
Mar 2, 2016·Journal of Controlled Release : Official Journal of the Controlled Release Society·B ChiangM R Prausnitz
Mar 17, 2011·Journal of Clinical Pharmacology·Eulogio BesadaPatrick Hardigan
Apr 28, 2004·The Veterinary Clinics of North America. Small Animal Practice·A Michelle Willis
Aug 24, 1999·American Journal of Ophthalmology·J O CarlsenW E Scott
Oct 1, 2014·Expert Opinion on Pharmacotherapy·Sky K ChewIvan Goldberg
Apr 7, 2010·Expert Opinion on Drug Safety·Mamun Q RahmanDonald M I Montgomery
Jul 5, 2005·Expert Opinion on Investigational Drugs·R David
May 10, 2017·Expert Opinion on Pharmacotherapy·Mark S DikopfDeepak P Edward
Oct 28, 2003·The Journal of Dermatology·Punita Kumari SodhiJohn Ratan
Jun 29, 2017·Expert Opinion on Drug Safety·Jed Asher Lusthaus, Ivan Goldberg
Aug 9, 2017·SLAS Discovery·Kerri J GrovePatrick J Rudewicz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.